dna-istock-518143098-ralwel--2
ralwel / iStockphoto.com
14 December 2018Biotech

ERS Genomics signs CRISPR deal with Lonza

ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
16 November 2026   The Swiss pharma giant will work with a Taiwan-based biotech’s ADC platform technologies to develop next-generation cancer therapies in a deal worth potentially more than $2bn, including $30m upfront.
Biotech
13 November 2026   Curiox claims confidential information shared during talks about a potential business partnership was used to develop a competing cell preparation system within months, despite the South Korean company spending years developing its own technology.
Biotech
11 November 2026   The parties granted each other the right to use their respective patented inventions in the field of infectious disease but are not obligated to make any payments in connection with the licences.